☰

Margalit B. Mokyr - Publications

Affiliations: 
University of Illinois at Chicago, Health Sciences Center, Chicago, IL 60612, United States 
Area:
Biochemistry, Immunology, Molecular Biology, Oncology
Tree Info Similar researchers PubMed Report error

47 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Berd DA, Braun D, Mokyr MB. Abstract 4755: Importance of an induction dose to the immunogenicity of cancer vaccines: A reverse translational study Cancer Research. 70: 4755-4755. DOI: 10.1158/1538-7445.Am10-4755  0.328
2008 Stoyanova T, Yoon T, Kopanja D, Mokyr MB, Raychaudhuri P. The xeroderma pigmentosum group E gene product DDB2 activates nucleotide excision repair by regulating the level of p21Waf1/Cip1. Molecular and Cellular Biology. 28: 177-87. PMID 17967871 DOI: 10.1128/Mcb.00880-07  0.316
2006 Mokyr MB, Place AT, Artwohl JE, Valli VE. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor. Cancer Immunology, Immunotherapy : Cii. 55: 459-68. PMID 15965646 DOI: 10.1007/s00262-005-0029-2  0.408
2006 Varadhachary A, Spadaro M, Engelmayer J, Blezinger P, Valli T, Petrak K, Pericle F, Mokyr MB, Forni G, Hayes TG. Talactoferrin alfa is an anti-cancer agent with activity in renal cell cancer (RCC) patients and a novel immunomodulatory mechanism of action Journal of Clinical Oncology. 24: 14648-14648. DOI: 10.1200/JCO.2006.24.18_SUPPL.14648  0.313
2004 Jovasevic VM, Gorelik L, Bluestone JA, Mokyr MB. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. Journal of Immunology (Baltimore, Md. : 1950). 172: 1449-54. PMID 14734721 DOI: 10.4049/Jimmunol.172.3.1449  0.747
2003 Donepudi M, Jovasevic VM, Raychaudhuri P, Mokyr MB. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunology, Immunotherapy : Cii. 52: 162-70. PMID 12649745 DOI: 10.1007/S00262-002-0345-8  0.715
2002 Sojka DK, Felnerova D, Mokyr MB. Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model. Cancer Immunology, Immunotherapy : Cii. 51: 200-8. PMID 12012107 DOI: 10.1007/S00262-002-0271-9  0.409
2001 Jovasevic VM, Mokyr MB. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression. Journal of Immunology (Baltimore, Md. : 1950). 167: 4895-901. PMID 11673494 DOI: 10.4049/Jimmunol.167.9.4895  0.732
2001 Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB. Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 166: 6491-9. PMID 11359799 DOI: 10.4049/Jimmunol.166.11.6491  0.763
2000 Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 164: 6230-6. PMID 10843675 DOI: 10.4049/Jimmunol.164.12.6230  0.773
2000 Sojka DK, La Motte RN, Mokyr MB. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells. Cancer Immunology, Immunotherapy : Cii. 49: 10-22. PMID 10782862 DOI: 10.1007/S002620050022  0.647
1999 Donepudi M, Quach DD, Mokyr MB. Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors. Cancer Immunology, Immunotherapy : Cii. 48: 153-64. PMID 10414470 DOI: 10.1007/S002620050560  0.727
1999 La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism. Journal of Immunology (Baltimore, Md. : 1950). 162: 4817-23. PMID 10202025  0.554
1998 La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 161: 6552-8. PMID 9862681  0.555
1998 Kalinichenko TV, Mokyr MB. Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor. Cancer Immunology, Immunotherapy : Cii. 46: 293-303. PMID 9756413 DOI: 10.1007/S002620050490  0.582
1997 Mokyr MB, Kalinichenko TV, Gorelik L. Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism. Cellular Immunology. 178: 152-61. PMID 9225006 DOI: 10.1006/Cimm.1997.1130  0.507
1996 La Motte RN, Rubin MA, Barr E, Leiden JM, Bluestone JA, Mokyr MB. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunology, Immunotherapy : Cii. 42: 161-9. PMID 8640844 DOI: 10.1007/S002620050266  0.587
1996 Gorelik L, Mokyr MB. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome. Cancer Immunology, Immunotherapy : Cii. 41: 363-74. PMID 8635194 DOI: 10.1007/Bf01526556  0.499
1995 Cook-Mills JM, Mokyr MB, Cohen RL, Perlman RL, Chambers DA. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma. Cancer Immunology, Immunotherapy : Cii. 40: 79-87. PMID 7882386 DOI: 10.1007/Bf01520288  0.58
1994 Weiskirch LM, Bar-Dagan Y, Mokyr MB. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunology, Immunotherapy : Cii. 38: 215-24. PMID 8168116 DOI: 10.1007/Bf01533512  0.542
1994 Gorelik L, Prokhorova A, Mokyr MB. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor Cancer Immunology Immunotherapy. 39: 117-126. DOI: 10.1007/Bf01525317  0.544
1993 Laude M, Russo KL, Mokyr MB, Dray S. Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy Cancer Immunology Immunotherapy. 36: 229-236. PMID 8439986 DOI: 10.1007/Bf01740904  0.454
1993 Rubin M, Mokyr MB. Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers. Cancer Immunology, Immunotherapy : Cii. 36: 37-44. PMID 8422666 DOI: 10.1007/Bf01789129  0.486
1993 Laude M, Russo KL, Mokyr MB, Dray S. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors Cancer Immunology Immunotherapy. 37: 89-96. PMID 8319246 DOI: 10.1007/Bf01517040  0.504
1992 Bartik MM, Baumgartel-Scofield BA, Mokyr MB. Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers. Cancer Immunology, Immunotherapy : Cii. 34: 79-89. PMID 1760820 DOI: 10.1007/Bf01741340  0.518
1992 Weiskirch LM, Mokyr MB. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. International Journal of Cancer. 51: 84-92. PMID 1563847 DOI: 10.1002/Ijc.2910510117  0.597
1991 Bartik MM, Ahn MC, Baumgartel BA, Hendricks RL, Mokyr MB. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy. Cancer Immunology, Immunotherapy : Cii. 32: 143-53. PMID 2289208 DOI: 10.1007/Bf01771449  0.536
1991 Weiskirch LM, Baumgartel BA, Barker E, Mokyr MB. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers. Cancer Immunology, Immunotherapy : Cii. 32: 353-63. PMID 1901031 DOI: 10.1007/Bf01741330  0.616
1990 Weiskirch LM, Barker E, Mokyr MB. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Cancer Immunology, Immunotherapy : Cii. 31: 129-38. PMID 2337902 DOI: 10.1007/Bf01744726  0.52
1989 Dray S, Mokyr MB. Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy. Medical Oncology and Tumor Pharmacotherapy. 6: 77-85. PMID 2657252 DOI: 10.1007/BF02985227  0.423
1988 Barker E, Mokyr MB. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan. Cancer Immunology, Immunotherapy : Cii. 25: 215-24. PMID 3677124 DOI: 10.1007/Bf00199150  0.557
1988 Wise JA, Mokyr MB, Dray S. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas. Cancer Immunology, Immunotherapy : Cii. 27: 191-7. PMID 3263205 DOI: 10.1007/Bf00205439  0.443
1988 Takesue BY, Bartik MM, Mokyr MB. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens. International Journal of Immunopharmacology. 9: 705-17. PMID 2891627 DOI: 10.1016/0192-0561(87)90042-7  0.594
1987 Mokyr MB, Dray S. Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy. Cancer Investigation. 5: 31-8. PMID 3555718 DOI: 10.3109/07357908709020304  0.385
1986 Bocian RC, Dray S, Ben-Efraim S, Mokyr MB. Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor. Cancer Immunology, Immunotherapy : Cii. 20: 61-8. PMID 3933817 DOI: 10.1007/Bf00199775  0.578
1986 Mokyr MB, Barker E. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers. Cancer Immunology, Immunotherapy : Cii. 23: 11-9. PMID 3490305 DOI: 10.1007/Bf00205549  0.583
1985 Mokyr MB, Colvin M, Dray S. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor International Journal of Immunopharmacology. 7: 111-122. PMID 3922904 DOI: 10.1016/0192-0561(85)90016-5  0.535
1984 Ye QW, Mokyr MB, Pyle JM, Dray S. Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor Cancer Immunology Immunotherapy. 16: 162-169. PMID 6561068 DOI: 10.1007/Bf00205423  0.528
1984 Bocian RC, Ben-Efraim S, Dray S, Mokyr MB. Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Cancer Immunology, Immunotherapy : Cii. 18: 41-8. PMID 6435857 DOI: 10.1007/Bf00205398  0.572
1983 Ben-Efraim S, Bocian RC, Mokyr MB, Dray S. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunology, Immunotherapy : Cii. 15: 101-7. PMID 6553510 DOI: 10.1007/Bf00199699  0.515
1980 Yamagishi H, Pellis NR, Mokyr MB, Kahan BD. Specific and non-specific immunologic mechanisms of tumor growth facilitation. Cancer. 45: 2929-33. PMID 7388736 DOI: 10.1002/1097-0142(19800615)45:12<2929::AID-CNCR2820451205>3.0.CO;2-9  0.362
1980 Mokyr MB, Bennett JA, Braun DP, Hengst JC, Mitchell MS, Dray S. Opposite effects of different strains or batches of same strain of BCG on in vitro generation of syngeneic and allogeneic antitumor cytotoxicity. Journal of the National Cancer Institute. 64: 339-44. PMID 6928226 DOI: 10.1093/Jnci/64.2.339  0.366
1978 Pellis NR, Mokyr MB, Babcock JR, Kahan BD. Progression of the immune response to solubilized tumor antigens. Immunological Communications. 7: 431-40. PMID 669751 DOI: 10.3109/08820137809047627  0.379
1978 Braun DP, Hengst JC, Mokyr MB, Dray S. Antitumor immunity in strain 2 guinea pigs immunized with potassium chloride extracts of L2C tumor cells. Journal of the National Cancer Institute. 60: 899-903. PMID 344900 DOI: 10.1093/jnci/60.4.899  0.373
1978 Mokyr M, Braun D, Usher D, Reiter H, Dray S. The development of in vitro and in vivo anti-tumor cytotoxicity in noncytotoxic, MOPC-315-tumor-bearer, spleen cells ?educated? in vitro with MOPC-315 tumor cells Cancer Immunology Immunotherapy. 4: 143-150. DOI: 10.1007/BF00204733  0.395
1977 Mitchell MS, Mokyr MB, Davis JM. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma. The Journal of Clinical Investigation. 59: 1017-26. PMID 863999 DOI: 10.1172/Jci108724  0.384
1976 Mitchell MS, Mokyr MB, Kahane I. Stimulation of lymphoid cells by components of BCG. Journal of the National Cancer Institute. 55: 1337-43. PMID 1107573 DOI: 10.1093/Jnci/55.6.1337  0.379
Show low-probability matches.